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tract in huntingtin is the root genetic cause of Huntington’s
disease (HD), a debilitating neurodegenerative disorder.
This seemingly slight change to the primary amino acid
sequence alters the physical structure of the mutant protein
and alters its activity. We have identiﬁed a set of G-quadru-
plex-forming DNA aptamers (MS1, MS2, MS3, MS4) that
bind mutant huntingtin proximal to lysines K2932/K2934
in the C-terminal CTD-II domain. Aptamer binding to
mutant huntingtin abrogated the enhanced polycomb
repressive complex 2 (PRC2) stimulatory activity conferred
by the expanded polyglutamine tract. In HD, but not
normal, neuronal progenitor cells (NPCs), MS3 aptamer
co-localized with endogenous mutant huntingtin and was
associated with signiﬁcantly decreased PRC2 activity.
Furthermore, MS3 transfection protected HD NPCs against
starvation-dependent stress with increased ATP. Therefore,
DNA aptamers can preferentially target mutant huntingtin
and modulate a gain of function endowed by the elongated
polyglutamine segment. These mutant huntingtin binding
aptamers provide novel molecular tools for delineating
the effects of the HD mutation and encourage mutant
huntingtin structure-based approaches to therapeutic devel-
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Huntington’s disease (HD) is a dominantly inherited neurodegen-
erative disorder with motor, cognitive, and psychiatric features
caused by expanded HTT CAG trinucleotide repeats that extend
a polyglutamine tract in the amino terminus of huntingtin.1 In
general, the longer the HTT CAG repeat expansion, the earlier
the age at onset of the clinical HD features.2,3 This inverse corre-
lation between CAG length and age at onset is also observed for
CAG repeat expansion mutations that cause other clinically
distinct inherited neurodegenerative disorders such as spinobulbar
muscular atrophy and spinocerebellar ataxias, with the mutation
in each case extending a polyglutamine tract in a different pro-
tein.4,5 The distinct protein contexts, in each of these disorders,416 Molecular Therapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The A
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cascade leading to the clinical symptoms of HD likely entails
some property conferred by the expanded polyglutamine tract
on mutant huntingtin.
Huntingtin is a ﬂexible 3,144-aa HEAT/HEAT-like (Huntingtin,
Elongation factor 3, protein phosphatase 2A, Target of rapamycin 1)
a-helical solenoid protein. Huntingtin likely serves as a scaffold for
multi-member complexes.6–8 Using puriﬁed human recombinant
huntingtins, with different polyglutamine segment lengths, we
have employed a variety of biochemical and biophysical methods
to delineate the domain structures of normal and mutant hunting-
tin.8 Huntingtins, regardless of polyglutamine length, possess a ma-
jor hinge region that delineates a 150-kDa amino-terminal arm,
comprising two domains (NTD-I and NTD-II), and a 200-kDa
C-terminal arm, with three domains (CTD-I, uncrosslinked domain
[UCD], and CTD-II).8 Consistent with a continuous a-helical struc-
ture, formed by stacking of adjacent HEAT/HEAT-like repeats, the
intramolecular contacts at sites within the domains of the amino-ter-
minal and C-terminal arms are modulated by the length of the poly-
glutamine segment in NTD-I.8 In addition, extending the length of
the polyglutamine tract enhances the ability of recombinant human
mutant huntingtin to stimulate the basal histone H3 lysine 27 trime-
thylation (H3K27me3) activity of polycomb repressive complex 2
(PRC2), as measured in a cell-free chromatin-nucleosome assay.9
This quantitative biochemical assay, which serves to monitor the ef-
fect of the polyglutamine tract length on a functional activity of hun-
tingtin, emerged from huntingtin’s critical role in regulating PRC2uthors.
vecommons.org/licenses/by/4.0/).
Figure 1. Screening of DNA Aptamers that Can
Preferentially Bind to Q78-Huntingtin
(A) A schematic illustrating DNA aptamer screening to
identify aptamers that bind preferentially to Q23- or Q78-
purified human recombinant huntingtin. (B) Bar graphs
presenting ELISA data show four representative aptamers
that bind significantly more to the purified Q78-huntingtin
(Q78) compared with Q23-huntingtin (Q23). Mean optical
densities at 405 nmwere measured by ELISA plate reader
from three independent experiments. *p < 0.05; **p <
0.01; ***p < 0.001 (two-sided unpaired Student’s t test).
(C) Thioflavin T fluorescence assay was performed with
Q78-huntingtin preferring aptamers, as well as positive
and negative control DNA aptamers. G-quadruplex-
forming DNA oligonucleotides c-myc and 45Ag produced
a strong positive signal, whereas ds26, which forms a
DNA duplex, and GCdx, which forms a stem-loop struc-
ture, had very weak signals just above baseline. Error bars
represent SEM.
www.moleculartherapy.orgdeposition of the chromatin histone H3K27me3 mark in developing
mouse embryos.9
These observations suggested to us that small molecules that pref-
erentially bind to the altered structure of mutant huntingtin,
compared with normal huntingtin, may selectively modulate the
gain of function conferred on the former by its longer polyglut-
amine tract. DNA aptamers, which are emergent in biomedical ap-
plications for biosensing, diagnostics, and therapeutics, are single-
stranded oligonucleotides that can be selected from large random
sequence pools through the speciﬁc high-afﬁnity associations of
these small molecules with target proteins.10,11 To provide an initial
proof of concept for small-molecule binding as a route to directly
modulate mutant huntingtin, we have screened a library of sin-
gle-stranded DNA aptamers to identify those that bind preferen-
tially to highly puriﬁed recombinant human mutant huntingtin
(78-glutamine tract), but not normal huntingtin (23-glutamine
tract). This strategy yielded a unique set of aptamers, binding the
C terminus, which we have evaluated for their potential ability toMolecular Tmodulate the gain of function endowed on
the mutant protein by its expanded polyglut-
amine tract.
RESULTS
A Set of G-Quadruplex DNA Aptamers that
Preferentially Bind to Mutant Huntingtin
We screened a library of DNA aptamers to
select for those able to discriminate between
highly puriﬁed recombinant human huntingtin
with a normal polyglutamine tract of 23 resi-
dues (hereafter Q23-huntingtin) or with an
expanded 78-residue polyglutamine tract (here-
after Q78-huntingtin), using a microarray plat-
form comprising 3,416 DNA aptamers (Fig-ure 1A). Because we expect subtle structural changes in mutant
huntingtin that are correlated to polyglutamine tract size,8 we chose
Q78-huntingtin to maximize the possibility to ﬁnd out mutant hun-
tingtin-speciﬁc DNA aptamers. From the DNA aptamers that tightly
bound to either huntingtin, subsets of aptamers that preferentially
bound to normal or to mutant huntingtin were then chosen using a
2-fold cutoff (Figure S1). Interestingly, the top 25 aptamers selected
as preferentially binding to Q78-huntingtin had a high percentage
of guanine nucleotides in their sequences (Figure S2). Seventeen of
these were selected and re-synthesized with a 50 biotin-moiety. In
an ELISA assay format, all 17 exhibited a signiﬁcantly higher level
of binding to mutant huntingtin, compared with normal huntingtin
(Figure 1B; Table S1). The top four, named MS1, MS2, MS3, and
MS4, were chosen for further characterization.
The presence of guanine-rich sequences in these Q78-huntingtin
preferential binding aptamers suggested that they may share a gua-
nine-rich DNA secondary structure, such as the G-quadruplex. Sec-
ondary structure analysis of the MS1, MS2, MS3, and MS4 aptamersherapy: Nucleic Acids Vol. 11 June 2018 417
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T (ThT) ﬂuorescence assay12,13 (Table S2). All four DNA aptamers
exhibited strong ﬂuorescence intensity signals, above background,
in a concentration-dependent manner, consistent with the presence
of G-quadruplexes (Figure 1C). Aptamer MS3 yielded the strongest
signal, surpassing the positive control 45Ag oligonucleotide. This
set of DNA aptamers that form intramolecular G-quadruplexes,
therefore, highlights a secondary DNA structural motif that, by
enabling preferential binding to Q78-huntingtin, can discriminate
the protein with the elongated polyglutamine tract from Q23-hun-
tingtin with the normal range polyglutamine segment.
Aptamers Bind the C-Terminal Arm of Q78-Huntingtin, near
K2932/K2934 in CTD-II
To determine whether the MS1, MS2, MS3, and MS4 aptamers bind
mutant huntingtin broadly or whether they may interact at a speciﬁc
site or sites along the 350-kDa protein, we initially monitored the
binding pattern using preformed complexes of biotinylated aptamers
bound to Q78-huntingtin that had then been digested with the cas-
pase-6 protease. This enzyme cleaves Q78-huntingtin (or Q23-hun-
tingtin) at amino acid residue 58614 (Figure 2A). This produced an
80-kDa amino-terminal polypeptide bearing the polyglutamine
stretch and a 270 kDa C-terminal polypeptide regardless of ap-
tamers binding (Figure S3). SDS-PAGE immunoblot analysis with
anti-biotin antibody revealed that, although chemical crosslinking
was not employed, the huntingtin-aptamer interaction was stable
because the biotinylated MS1 aptamer signal was detected coinci-
dent with both the uncleaved Q78-huntingtin-aptamer complex
(350 kDa) and the 270-kDa C-terminal fragment, whereas the
amino-terminal 80-kDa polypeptide, containing the polyglutamine
segment, was not detected (Figure 2B). The same pattern was observed
from cleaved complexes of Q78-huntingtin and biotinylated-MS2,
-MS3, and -MS4 (Figure 2C). Immunoblot with huntingtin-speciﬁc
antibodies HF1 (epitope residues 1,981–2,580) andmAb2166 (epitope
residues 181–810) (Figures 2B and 2C) conﬁrmed the expected iden-
tities of the cleavage polypeptides.
A subsequent analysis narrowed the interaction site of the strongest
Q78-huntingtin binder, MS3, by surface lysine methylation (SLM)
of preformed Q78-huntingtin-MS3 complex, followed by mass
spectrometry (liquid chromatography-mass spectrometry [LC/MS/
MS]), as judged relative to SLM of controls: Q78-huntingtin after
interaction with a nonspeciﬁc aptamer GCdx, which showed little
or no binding to either Q23- or Q78-huntingtin (Figure 2F) and
Q78-huntingtin without aptamer. We also performed SLM with
LC/MS/MS for the same set of Q23-huntingtin, such as bound
with either MS3 or GCdx and no aptamer. Because SLM modiﬁes
exposed Lys or Arg residues,15 the data were analyzed to identify
the Lys and Arg residues whose methylation was hindered by MS3
binding, compared with modiﬁed peptides in control samples. The
overall amounts of methylated peptides from all samples tested
were comparable (Figure S4). First, we evaluated 49 and 54 Lys/
Arg residues from methylated peptides (>2) in Q23- and Q78-hun-
tingtin alone, respectively (Table S3). To quantify the differentials,418 Molecular Therapy: Nucleic Acids Vol. 11 June 2018we assigned a score for each modiﬁed site by considering the spec-
iﬁcity and magnitude of change of the methylated peptides from
MS3-bound Q23- or Q78-huntingtin compared with control GCdx
aptamer-bound and unbound Q23- or Q78-huntingtin (equation
is presented in Materials and Methods). Lysines K2932/K2934 had
an outstanding score (40) in Q78-huntingtin compared with other
sites (<10), while showing a score close to zero in Q23-huntingtin
(Figures 2D and 2E). These results strongly suggest that these two
residues within the CTD-II domain of the C-terminal arm of
Q78-huntingtin may be in the proximity of the MS3 aptamer bind-
ing site or may be directly involved in MS3 aptamer binding. To test
this prediction, we replaced the CTD-II K2932/K2934 lysine resi-
dues of Q78-huntingtins with aspartic acid (D) residues (Figure 2F).
For comparison, we evaluated binding to Q78-huntingtin with a
substitution at another lysine residue within the C-terminal arm
UCD domain: K2449D (Figure 2F), a site exhibiting the second
highest SLM score (Figure 2E; Table S3). We also tested a triple-
mutant Q78-huntingtin K2449D/K2932D/K2934D with both the
UCD and CTD-II substitutions (Figure 2F). Consistent with the
SLM result of MS3 binding in the proximity of the K2932/K2934
residues, the Q78-huntingtin K2932D/K2934D double mutation
nearly eliminated the interaction with MS3, which showed the pref-
erential afﬁnity for the non-mutated Q78-huntingtin compared with
non-mutated Q23-huntingtin, whereas the K2449D mutant showed
slightly reduced afﬁnity (Figure 2F). Notably, although decreased
compared with unmutated Q78-huntingtin, biotinylated MS3 ex-
hibited a stronger interaction with the K2449D/K2932D/K2934D
triple mutant Q78-huntingtin, relative to the K2932D/K2934D dou-
ble mutant Q78-huntingtin. This implies that the MS3 interaction
likely entails access that can be modulated by features formed
by the neighboring UCD and CTD-II domains in the context of
Q78-huntingtin with its elongated polyglutamine segment in
NTD-I. Therefore, our ﬁnding strongly suggests that the polyglut-
amine expansion at the very amino-terminal region globally alters
the secondary and/or tertiary structure of mutant huntingtin, result-
ing in the formation of preferential binding sites near its end of the
C-terminal region for aptamers.
Aptamer Binding Abrogates the Heightened PRC2-Stimulating
Activity of Q78-Huntingtin
In addition to its physical impact on mutant huntingtin structure,
the elongated polyglutamine tract also endows a gain of function.
We monitor one such activity, heightened stimulation of PRC2 ac-
tivity, that provides a valuable biochemical assay with which to
conduct huntingtin structure-function studies. This abnormal activ-
ity of mutant huntingtin emerged from studies of normal hunting-
tin’s essential role as a facilitator of the chromatin regulator during
embryonic development.9 Normal huntingtin stimulates PRC2-
mediated deposition of the histone H3K27me3 mark in cells and,
with puriﬁed recombinant proteins, in cell-free PRC2 nucleosome-
array histone H3K27me3 assay. However, mutant huntingtins
exceed this level of stimulation in a manner that increases with
the length of the expanded polyglutamine tract.9,16 It is not yet
known how this effect is achieved. However, we have observed
Figure 2. CTD-II Domain near K2932/K2934 in Mutant Huntingtin Is a Potential Binding Site of the MS3 Aptamer
(A) A schematic view of huntingtin with five domains delineated as previously described.8 Caspase-6 cleavage site is indicated by the red arrow. The polyglutamine tract is
denoted by the green bar. (B) The biotinylated DNA aptamer MS1 (Biotin, first blot) was detected in uncleaved Q78-huntingtin, and the larger fragment from caspase-6
cleavage of Q78-huntingtin with an anti-biotin antibody. The representative blot showed that most of the aptamer appeared to be bound to the C-terminal fragment and un-
cleaved huntingtin (arrows), but not the amino-terminal fragment (arrowhead), which was confirmed by re-probing the blot with a huntingtin C-terminal antibody (HF1, second
blot) and an amino-terminal antibody (mAb2166, third blot). The experiment was repeated three times. (C) The same experiment was performed for the remaining biotinylated
aptamers (MS2, MS3, MS4) and MS1. The representative immunoblot demonstrated that all aptamers preferentially bound to the C terminus of Q78-huntingtin. The
experiment was repeated three times. (D and E) SLM analysis was performed with the huntingtin-aptamer complex and huntingtin alone. Themethylated lysine residues were
detected by LC/MS/MS and assigned a score based on the equation described in the Materials and Methods. The bar graphs showing the score of Q23- (D) and Q78- (E)
huntingtin revealed that K2932/K2934 in CTD-II was the most probable binding site of MS3 on Q78-huntingtin. (F) Representative immunoblot showing purified Q23-, Q78-,
Q78 K2449D-, Q78 K2932D/K2934D-, and Q78 K2449D/K2932D/K2934D-huntingtin bound with biotinylated MS3 or GCdx aptamers by probing with an anti-biotin
antibody (Biotin) and an anti-huntingtin antibody (mAb2166). The location of full-length huntingtin is indicated by the arrow in both immunoblots. The asterisk marked a blurry
band detected by anti-biotin antibody, but not by mAb2166, implying that a protein (or more than one) from insect cells, showing affinities to MS3 aptamer, was particularly
enriched in Q78 K2449D-purified protein and less in Q78 K2932D/K2934D-purified proteins. The experiment was repeated three times.
www.moleculartherapy.org
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Figure 3. Aptamer Binding Selectively Reduces
Mutant Huntingtin’s PRC2-Stimulating Activity
(A) The affinities of Q78-huntingtin alone and huntingtin-
aptamer complexes to PRC2 were compared by immu-
noprecipitation with an anti-EZH2 antibody and an anti-
huntingtin antibody (HP-1), followed by immunoblotting
for huntingtin and EZH2. The experiment was repeated
three times. (B) Autoradiogram of bands of 3H-methyl
histone H3 produced by PRC2 in the absence and
presence of mutant-huntingtin-preferring DNA aptamers.
Bottom: the bar graph of the band densitometry results,
showing that aptamer binding significantly reduced the
ability of mutant huntingtin to enhance basal PRC2 ac-
tivity. Mean band intensities were measured from three
independent experiments. Asterisks indicate statistically
significant differences compared with unbound Q78-
huntingtin. Error bars represent SEM. *p < 0.05 (two-sided
unpaired Student’s t test).
Molecular Therapy: Nucleic Acidsthat whereas normal huntingtin and mutant huntingtin both can
interact (directly or indirectly) with PRC2 composed of EED,
Rbp48, SUZ12, and EZH2, mutant huntingtin appears to interact
more strongly, as judged by co-immunoprecipitation (data not
shown and in preparation of this manuscript). We reasoned that
because the G-quadruplex-forming aptamers preferentially bind to
mutant huntingtin rather than normal huntingtin, the binding of
these small molecules to the former may be expected to inﬂuence
mutant huntingtin’s exaggerated functional interaction with PRC2.
Pre-binding of recombinant human Q78-huntingtin to DNA
aptamers MS1, MS2, MS4, and especially MS3 decreased the inter-
action of mutant huntingtin with the PRC2 complex, as revealed
by the reduced signals detected for huntingtin and EZH2 in co-im-
munoprecipitates, compared with the levels observed in the co-im-
munoprecipitates when unbound Q78-huntingtin was complexed
with PRC2 (Figure 3A). The apparent decrease in the interaction
with the complex implied that the aptamer binding may also atten-
uate Q78-huntingtin’s heightened PRC2-stimulating activity. This
hypothesis was tested using our previously reported cell-free recon-
stituted PRC2 nucleosome-array histone H3K27me3 assay.9 At high
concentrations (1:10 huntingtin/aptamer molar ratio), the MS1,
MS2, MS3, and MS4 aptamer-bound recombinant human Q78-hun-
tingtins all exhibited signiﬁcantly decreased PRC2 stimulation,
compared with unbound Q78-huntingtin. MS3 binding signiﬁcantly
decreased PRC2 stimulation even at a 1:1 aptamer-huntingtin ratio
(Figure 3B). Thus, these aptamers, especially MS3, may signiﬁcantly
reduce mutant huntingtin’s over-enhancement of PRC2 activity,
perhaps by decreasing its afﬁnity to PRC2.
Aptamer Binding Abrogates the Heightened PRC2-Stimulating
Activity of Endogenous Mutant Huntingtin in Cultured HD-
Derived NPCs
Endogenous mutant huntingtin is also associated with heightened
stimulation of PRC2 inmouseHdhQ111 CAG repeat knockin embry-420 Molecular Therapy: Nucleic Acids Vol. 11 June 2018onic stem cells.9,16 Moreover, the signiﬁcance of PRC2 in adult neu-
rons was reported, showing the critical role of PRC2-dependent tran-
scriptional changes on progressive and fatal neurodegeneration in
mice.17 We therefore assessed whether the most functional DNA ap-
tamer MS3 may discriminate the endogenous mutant and normal
huntingtins expressed in previously reported18 human HD60i4 and
HD17m8 neuronal progenitor cells (NPCs), from an individual
with the CAG expansion mutation and from a normal individual,
respectively, and if so, whether the presence of cell-transfected ap-
tamer may modulate PRC2 deposition of the histone H3K27me3
mark. Preferential interaction of MS3 with mutant huntingtin in
transfected HD60i cells, compared with normal huntingtin in trans-
fected HD17m8 cells, was supported by three lines of evidence. In a
streptavidin-conjugated bead pull-down assay, the MS3-beads pro-
duced a 3.6-fold more efﬁcient pull-down of huntingtin from
HD60i4 lysate compared with HD17m8 lysate, although total hun-
tingtin levels in the normal and mutant cells were similar (Figures
4A and 4B). In addition, whereas transfected FAM-conjugated
GCdx control DNA oligonucleotide produced similar ﬂuorescence
intensities and puncta sizes in HD17m8 and HD60i4 NPCs, as de-
tected by confocal microscopy (Figures S5A and S5C), transfection
with FAM-conjugated MS3 aptamer yielded puncta of increased
size and intensity in HD60i4 cells, compared with the HD17m8 cells
(Figures S5A and S5B). Furthermore, analysis of co-immunostaining
with an anti-huntingtin antibody (Figure 4C) and FAM-conjugated
MS3 aptamer revealed a signiﬁcantly increased co-localization of
the signals in HD60i4, compared with HD17m8, neuronal cells
(Figure 4D).
In order to monitor cellular PRC2 activity in the HD60i4 and
HD17m8 cultured human NPCs, we ﬁrst optimized an AlphaLISA
H3K27me3 assay that could quantify the previously reported impact
of the CAG expansion mutation in mouse embryonic stem cells
and immortalized mouse striatal cells (see Materials and Methods;
Figure 4. The MS3 Aptamer Can Bind to Endogenous Huntingtin and Abrogate Cellular PRC2 Activity
(A) Representative immunoblot showing streptavidin pull-down of huntingtin with or without biotinylated MS3 from the extracts of NPCs with CAG17/17 (HD17m8) and
CAG60/18 (HD60i4) by probing with anti-huntingtin antibody (mAb2166). Huntingtin levels in the input are also shown (right). Both b-tubulin andGAPDHwere used as loading
controls. The experiment was repeated five times. (B) Densitometry analysis for streptavidin pull-down of endogenous huntingtin, normalized by huntingtin levels in the input
that were normalized by b-tubulin. Mean band intensities were measured from three independent experiments. Error bars represent SEM. ***p < 0.001 (two-sided unpaired
Student’s t test). (C) Fluorescence images of HD17m8 and HD60i4 NPCs, showing the pattern of Hoechst 33342 (a and f) nuclei, transfected 6-FAM-conjugated MS3
(b and g), and anti-huntingtin (c and h) immunostaining, illustrating the significantly higher correlation between FAM-MS3 and cellular huntingtin in HD60i4 NPCs compared
with HD17m8. The merged images (d and i) indicated by the open boxes are shown at a higher magnification in the adjacent columns (e and j). White arrowheads in (e) and (j)
indicate FAM-MS3 aptamers that co-localized with cellular huntingtin. Scale bar, 10 mm. (D) Pearson’s correlation coefficient for co-localization analysis of MS3-huntingtin
signal overlap in HD17m8 and HD60i4 NPCs were displayed in a vertical boxplot. Mean degree of co-localization was measured in nine images per cell line. Error bars
represent SEM. p value as determined by a two-sided unpaired Student’s t test. (E) The cellular H3K27me3 levels measured by AlphaLISA signal were significantly decreased
by MS3 aptamer transfection in HD60i4 NPCs specifically, but not by stem-loop DNA oligonucleotides (GCdx). Mean AlphaLISA signal counts were measured from three
independent experiments. Error bars represent SEM. *p < 0.05 (one-way ANOVA with Tukey post hoc test).
www.moleculartherapy.orgFigure S6). This optimized AlphaLISA H3K27me3 assay detected
increased signal/cell for mock-transfected HD60i4 NPCs, which
express mutant huntingtin, compared with mock-transfected
HD17m8 NPCs, which express only normal huntingtin. Further-
more, transfection of HD60i4 cells with MS3 aptamer yielded signif-icantly decreased signal/cell, compared with mock transfection, while
signal/cell was relatively unchanged in the MS3-transfected HD17m8
cells. Transfection with control aptamer GCdx mildly, although not
signiﬁcantly, decreased the AlphaLISA signal/cell in both the mutant
and the normal NPCs (Figure 4E). Taken together, these ﬁndings inMolecular Therapy: Nucleic Acids Vol. 11 June 2018 421
Figure 5. The MS3 Aptamer Protects HD Human NPC against Starvation-
Dependent Stress
(A) The cellular ATP levels measured by bioluminescent assay (Promega) were
significantly increased by MS3 aptamer transfection, but not by stem-loop DNA oli-
gonucleotides (GCdx) in HD60i4 NPCs. Mean cellular ATP contents per cell were
measured from four independent experiments. Error bars represent SEM. **p < 0.01
(one-way ANOVA with Tukey post hoc test). (B–D) The viability of HD60i4 NPCs
starved in total starvation medium (HBSS) (B) for 6 hr was significantly increased by
MS3 aptamer transfection, but not by GCdx. The viabilities of NPCs treated with
0.2 mM hydrogen peroxide (C) for 6 hr or 0.125 mM doxorubicin (D) for 24 hr were
affected by neither MS3 nor GCdx transfection. Values are presented as the mean of
three independent experiments. Error bars represent SEM. **p < 0.01 (one-way
ANOVA with Tukey post hoc test).
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422 Molecular Therapy: Nucleic Acids Vol. 11 June 2018transfected human HD NPCs support a preferential interaction of
MS3 aptamer with endogenous mutant huntingtin that is associated
with a diminution in the heightened stimulation of PRC2 that is
one of the functional consequences of the impact of the elongated
polyglutamine tract on the mutant protein.
Aptamer Binding Also Improves Energy Balance and Starvation-
Dependent Stress Response in HD hNPCs, but Not in Normal
hNPCs
The effect of MS3 on modulation of PRC2 activity prompted us to
investigate whether DNA aptamer binding could possibly ameliorate
mutant huntingtin toxicity. We have previously reported that the
expanded polyglutamine repeats in huntingtin resulted in energetic/
metabolic deﬁcits in HD subjects as evidenced by decreased energy
charge (ATP/ADP ratio) and ATP levels in human lymphoblastoid
cell lines, mouseHdhCAG knockin embryonic stem cells, and human
induced pluripotent stem cells (iPSCs)/NPCs.18–20 To determine the
effect of MS3 on cellular ATP levels in human NPCs HD17m8 and
HD60i4, the cells were mock transfected with MS3 or GCdx. As ex-
pected, ATP levels in HD60i4 cells were signiﬁcantly lower than
HD17m8. Interestingly, MS3 transfection signiﬁcantly increased the
ATP levels in HD60i4 cells compared with mock- and GCdx-trans-
fected cells (Figure 5A), while there was no effect of MS3 or GCdx
in HD17m8 cells. The improved energy homeostasis in HD human
NPCs by MS3 prompted us to determine its impact on response of
cells to various cellular stresses because huntingtin is reported to be
involved in cell stress responses21 that are largely associated with
metabolic processes.22 Compelling evidence suggests that increased
oxidative stress and mitochondrial dysfunction may underlie HD
pathogenesis.23 Oxidative stress can result in DNA damage, and
thus HD is associated with increased incidence of mutations. Interest-
ingly, normal huntingtin has been reported to play a role in oxidative
DNA damage repair, whereas mutant huntingtin is unable to facilitate
it.24 First, we compared the cell viabilities of normal and HD human
NPCs under three different stresses: starvation, oxidative stress, and
DNA damage. Interestingly, HD60i4 revealed signiﬁcant reduction
in cell viability under all three stress conditions compared with
HD17m8 (Figure S7), indicating that mutant huntingtin could
adversely affect these stress responses. In order to check the effect
of MS3 on cell viability under these stress conditions, HD17m8 and
HD60i4 were either mock, MS3, or GCdx transfected and subjected
to each stress condition for an indicated time/concentration. While
MS3-transfected HD60i4 showed signiﬁcantly improved cell viability
in response to starvation-dependent stress by almost achieving
HD17m8 levels (Figure 5B), no effect on cell viability was observed
under oxidative stress and DNA damage conditions (Figures 5C
and 5D). Thus, MS3 aptamer binding to endogenous mutant hun-
tingtin can ameliorate metabolic deﬁcits of HD phenotype and
enhance ability to combat starvation-mediated stress.
DISCUSSION
We have identiﬁed a speciﬁc set of DNA aptamers that preferentially
bind to full-length huntingtin with an expanded polyglutamine tract,
providing novel molecular tools that may modulate the structure and
www.moleculartherapy.orgfunction of the mutant protein, unlike the previously reported gua-
nine-rich oligonucleotides that bind to the exon 1-encoded short
amino-terminal huntingtin fragments inhibiting their aggrega-
tion.25–27 In fact, two DNA aptamers (T30923 and T40216 as clone
ID) of the previously identiﬁed guanine-rich oligonucleotides25
were included in our 3416 DNA aptamers. Interestingly, they could
not be shortlisted even as tightly bound aptamers (Figure S1),
implying the unique speciﬁcity of our DNA aptamers toward full-
length mutant huntingtin and the reliability of the microarray
screening. However, it is not clear why all four WS (Q23-hunting-
tin-preferring) DNA aptamers could not be validated in the same
ELISA assay showing low afﬁnities to both Q23- and Q78-huntingtin.
One of the possible reasons of exaggerated afﬁnity toward Q23-hun-
tingtin in the microarray may be because of Alexa 488 modiﬁcation,
which reacts with primary amines of huntingtin, on top of structural
differences of Q23-huntingtin and Q78-huntingtin. We may need
another screening strategy employing a crosslinking method to
modify huntingtin or use unmodiﬁed huntingtin to screen Q23-hun-
tingtin-speciﬁc DNA aptamers. In addition to the intrinsic beneﬁts of
aptamers (e.g., small size, easy chemical modiﬁcation for labeling, and
stability), the unique speciﬁcity of our aptamers to the altered second-
ary/tertiary structure of huntingtin as an outcome of posttranslational
modiﬁcations or polyglutamine tract size may serve to support the
development of aptamers as huntingtin biosensors. In particular,
we clearly demonstrated the predominant binding of MS3 to endog-
enous mutant huntingtin in live human cells, indicating that the
structural features of puriﬁed huntingtin precisely mirror endogenous
huntingtin including the effects of polyglutamine expansion. The
ﬁnding that the MS3 DNA aptamer interacts preferentially with
Q78-huntingtin at a location at or near CTD-II K2932/K2934,
perhaps involving UCDK2449, reasonably predicts that the preferen-
tial interactions of the other G-quadruplex-forming aptamers (MS1,
MS2, and MS4) within the C-terminal arm of Q78-huntingtin are
likely to involve the same features. It is noteworthy that the preferen-
tial binding of these DNA aptamers to Q78-huntingtin within the
CTD-II domain, but not to Q23-huntingtin, is consistent with our
previous report that the elongated polyglutamine tract of Q78-hun-
tingtin subtly alters the physical structure of the entire mutant
huntingtin molecule.8 A single-molecule electron microscopy and
chemical crosslinking-LC/MS/MS analysis show that Q23-huntingtin
forms a spherical solenoid (with open cavity) in which the NTD-I
domain of the amino-terminal arm is in close proximity to the
CTD-I and CTD-II domains of the C-terminal arm. In Q78-hunting-
tin, the latter proximities of these domains with NTD-I are signiﬁ-
cantly altered,8 implying a novel structural opportunity that would
permit access to residues in the CTD-II domain to small molecules
that preferentially bind Q78-huntingtin, such as our set of G-quadru-
plex-forming DNA aptamers.
G-quadruplex-forming molecules that can regulate biological pro-
cesses through direct binding to speciﬁc proteins are emerging as
promising therapeutic agents.28–30 Indeed, all four aptamers tested
decreased mutant huntingtin’s enhancement of PRC2 activity in
our cell-free PRC2 assay, and transfection of MS3 aptamer resultedin the reduced histone H3K27me3mark only in HDNPCs expressing
mutant huntingtin, measured by our bead-based PRC2 cellular assay.
These ﬁndings support the general proposal that the HEAT/HEAT-
like repeat domains of huntingtin can serve as a structural framework
that interacts with PRC2 components, thereby facilitating the cata-
lytic activity of the enzyme.9 The detailed mechanism of hunting-
tin-PRC2 interaction is still elusive. However, binding of the DNA
aptamers, which involves sites in the C-terminal CTD-II domain, is
able to abrogate the heightened physical and functional interaction
of Q78-huntingtin with PRC2, despite the presence of the elongated
polyglutamine segment in the NTD-I domain. We also hypothesized
that the aptamer binding could potentially contribute to relieve one or
more HD phenotypic defects, such as energy deﬁcit and hyper-
vulnerability to cellular stresses. Indeed, MS3-transfected HD hNPCs
revealed increased ATP levels and cell viability against starvation-
induced stress. Because MS3 showed signiﬁcantly increased afﬁnity
to endogenous Q62-huntingtin, it would be an interesting question
to know whether MS3 can preferably bind to mutant huntingtin
with shorter glutamine expansion, such as Q46-huntingtin. To
directly test this, we performed the in vitro binding experiment
with Q23-, Q46-, and Q78-huntingtin using biotinylated MS3 (Fig-
ure S8). Indeed, MS3 showed increased afﬁnity to Q46-huntingtin,
as well as Q78-huntingtin, compared with Q23-huntingtin. Thus,
our DNA aptamers, such as MS3, can be developed to target mutant
huntingtin with various polyglutamine lengths from adult-onset
ranges of CAG expansion to juvenile-onset ranges.
We propose that the transfectedMS3 aptamermay alter interaction of
mutant huntingtin interaction with other protein complexes involved
in metabolic regulation resulting in a protective effect without alter-
ation in mutant huntingtin level in MS3-transfected human HD
NPCs (Figure S5D). Based on these ﬁndings, it can be reasonably hy-
pothesized that polyglutamine tract-length-dependent alteration of
huntingtin secondary/tertiary structure may generate novel sites for
protein-protein interaction, as well as abrogate certain interactions.
These altered protein-protein interactions in mutant huntingtin
may potentially result in its gain of function, and binding of aptamers
at the novel interaction sites may revert the phenomenon, at least in
part, by blocking or reducing these aberrant interactions. Extensive
studies have identiﬁed numerous huntingtin binding partners
involved in various cellular functions, but how those functions are
affected by mutant huntingtin is largely unknown. Our aptamers
can provide a novel way to understand the dynamics of protein com-
plex interacted with mutant huntingtin in the absence or presence of
metabolic stress.
Our ﬁndings, therefore, provide a proof-of-concept that abnormal
activities conferred on mutant huntingtin by the expanded poly-
glutamine tract, encoded by the HD CAG expansion mutation,
can be countermanded by delineating and exploiting the altered
structural features of mutant huntingtin. The set of four G-quadru-
plex-forming DNA aptamers that target certain residues in the
CTD-II, and possibly the UCD domain of the C-terminal arm of
mutant huntingtin, discriminate mutant huntingtin from normalMolecular Therapy: Nucleic Acids Vol. 11 June 2018 423
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cise residues that are engaged, the structural changes in mutant
huntingtin that are associated with dial-back of heightened func-
tion, a platform for generating mutant huntingtin-binding biosen-
sors, and ﬁnally, the delineation of biological processes in cells and
potentially in animal systems that are affected by mutant hunting-
tin. Also, considering huntingtin as a continuous a-helical sole-
noid, the detailed mechanism of MS3 binding to mutant hunting-
tin, including potentially signiﬁcant structural changes caused by
MS3 binding, should be pursued through independent studies,
such as obtaining high-resolution images of MS3-bound mutant
huntingtin structure, which will be important to develop our
aptamer binding sites into therapeutic target sites for full-length
mutant huntingtin.
MATERIALS AND METHODS
Full-Length Human Recombinant Huntingtin Expression and
Purification
Expression of full-length Q23-, Q46-, and Q78-huntingtin from our
pALHDQ23, pALHDQ46, and pALHDQ78 constructs was done us-
ing the Baculovirus Expression system (Invitrogen).8 Three lysine as-
partic acid (KD) mutant huntingtin constructs (K2449D, K2932D/
K2934D, K2449D/K2932D/K2934D) were generated by submission
of the DNA sequences to Genscript (Piscataway, NJ, USA), which
provided synthesized DNA in the pFastBac1 vector using SalI/SacII
restriction digest and standard molecular biology techniques. The
preparation and puriﬁcation of full-length huntingtin was carried
out as previously described.8
Aptamer Screening Using the Recombinant Purified Huntingtin
To screen for small-molecule DNA aptamers that preferentially and
speciﬁcally interact with huntingtin in a polyglutamine-dependent
fashion, we used puriﬁed recombinant huntingtin as the bait. This
screening was performed by using a protein-binding DNA aptamer
microarray collection containing 3,416 aptamer probes in a single-
strand DNA format (LC Science) with Alexa ﬂuorophore 488 (Molec-
ular Probes)-labeled Q23-huntingtin and Q78-huntingtin at the
condition suggested by the manufacturer (Table S4). All raw data
were processed and ﬁltered for quality control, including back-
ground-subtracted and normalized signals and p values for the scat-
terplot of the image signal, to obtain statistically signiﬁcant data.
DNA aptamers that bound to huntingtin tightly were further selected
by using a cutoff value of 50, which is the average of total aptamers’
signal intensities. The DNA aptamers that preferentially bound to
mutant huntingtin were further validated by ELISA using biotinylated
DNA aptamers.
ELISA Assay
Huntingtin proteins (Q23 and Q78) (1 pmol/well) were coated in
96-well plates (Nunc MaxiSorp) in Tris-buffered saline (TBS) for
16–20 hr at room temperature. The wells were blocked with TBS
buffer (10 mM Tris-HCl [pH 8.0], 0.15 M NaCl, 100 mL/well)
containing 2 mg/mL BSA for 1 hr at room temperature. Indicated
biotinylated aptamers (50 pmol) were added to the empty wells (con-424 Molecular Therapy: Nucleic Acids Vol. 11 June 2018trols) or wells coated with huntingtin and incubated for 2 hr at room
temperature. After thoroughly washing with Tris-buffered saline with
Tween 20 (TBST) (200 mL, 3), diluted streptavidin-POD (1:10,000
dilution in TBST with 1% BSA, 100 mL/well; Roche) was added to
all wells and incubated for 1 hr at room temperature. The streptavi-
din-POD solution was removed and washed thoroughly with TBST
(200 mL, 3). Peroxidase substrate (2,20-azino-di-3-ethylbenzthiazo-
line-6-sulfonic acid and H2O2) was added and shaken until a blue-
green color developed that was read at 405 nm. The intensity of color
was proportional to biotinylated aptamer bound to huntingtin.
Thioflavin T Fluorescence Assay
DNA oligonucleotides (Integrated DNA Technologies) were heated
at 90C for 10 min in millipure water at 4, 20, or 40 mM. The oligo-
nucleotides were diluted 1:2 in 100 mM Tris-HCl (pH 7.5),
100 mM KCl and slowly cooled to room temperature. Oligonucleo-
tides were mixed with 1 mM thioﬂavin T (Sigma-Aldrich) and added
to a 96-well assay plate to yield 1, 5, and 10 mM ﬁnal concentrations of
oligonucleotide and 0.5 mM ﬁnal concentration of thioﬂavin T. Sam-
ples were mixed in triplicate. Fluorescence intensity was measured
with a plate reader (Tecan Inﬁnite M200) with excitation at 425 nm
and emission at 490 nm.
Identification of Huntingtin Aptamer Binding Site
To identify whether the aptamers (MS1, MS2, MS3, and MS4)
bound preferentially to the amino terminus of huntingtin bearing
the polyglutamine region or to the C-terminal region of mutant
huntingtin (Q78-huntingtin), we incubated biotinylated aptamers
with Q78-huntingtin in a 10:1 molar ratio for 2 hr at room temper-
ature followed by removal of free aptamers by subjecting the com-
plex to spin gel-ﬁltration columns (Sigma-Aldrich). Q78-hunting-
tin-aptamer complex was then subjected to caspase-6 digestion
for 2 hr at 30C followed by SDS-PAGE and western blotting.
The nitrocellulose membrane was probed with anti-biotin antibody
to detect biotinylated aptamer-bound huntingtin followed by strip-
ping and re-probing with anti-huntingtin antibodies with epitopes
in the amino- (mAb2166 from Millipore) and C-terminal (HF1)
regions.
Surface Lysine Methylation Analysis with LC/MS/MS
The MS3 or GCdx aptamers were incubated with recombinant Q23-
and Q78-huntingtin in a 5:1 molar ratio for 2 hr at room temperature.
Huntingtin-aptamer complexes were mixed with a ﬁnal concentra-
tion of 20 mM borane-dimethylamine complex (Sigma-Aldrich)
and 40 mM formaldehyde (Sigma-Aldrich), and incubated 2 hr at
4C. The reactions were further incubated with an additional ﬁnal
concentration of 10 mM borane-dimethylamine complex for 12 hr
at 4C. The reactions were quenched by adding a ﬁnal concentration
of 125 mM Tris-HCl (pH 8.0). The methylated huntingtin-aptamer
complexes were separated on a 7.5% Tris-Glycine polyacrylamide
gel (Bio-Rad), and the protein bands of interest were excised
for LC/MS/MS analysis. Each sample was reduced with 1 mM
DTT for 30 min at 60C and then alkylated with 5 mM iodoacetamide
for 15 min in the dark at room temperature. Gel pieces were then
www.moleculartherapy.orgsubjected to a modiﬁed in-gel trypsin digestion procedure.31 Gel
pieces were washed and dehydrated with acetonitrile for 10 min fol-
lowed by removal of acetonitrile. Pieces were then completely dried
in a SpeedVac. Rehydration of the gel pieces was with 50 mM
ammonium bicarbonate solution containing 12.5 ng/mL modiﬁed
sequencing-grade trypsin (Promega) at 4C. Samples were then
placed in a 37C room overnight. Peptides were later extracted by
removing the ammonium bicarbonate solution, followed by one
wash with a solution containing 50% acetonitrile and 1% formic
acid. The extracts were then dried in a SpeedVac (1 hr). Chymo-
trypsin (Roche Diagnostics) was then added to both the dried extracts
and the residual gel pieces, and digested at room temperature over-
night. The extraction of peptides was repeated and then dried. The
samples were then stored at 4C until analysis. On the day of analysis,
the samples were reconstituted in 5–10 mL of high-performance liquid
chromatography (HPLC) solvent A (2.5% acetonitrile, 0.1% formic
acid). A nano-scale reverse-phase HPLC capillary columnwas created
by packing 2.6 mm C18 of spherical silica beads into a fused silica
capillary (100 mm inner diameter  30 cm length) with a ﬂame-
drawn tip.32 After equilibrating the column, each sample was loaded
via a Famos auto sampler (LC Packings) onto the column. A gradient
was formed and peptides were eluted with increasing concentrations
of solvent B (97.5% acetonitrile, 0.1% formic acid). As each peptide
was eluted, they were subjected to electrospray ionization and then
entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer
(Thermo Fisher Scientiﬁc). Eluting peptides were detected, isolated,
and fragmented to produce a tandem mass spectrum of speciﬁc frag-
ment ions for each peptide. Peptide sequences (and hence protein
identity) were determined by matching protein or translated nucleo-
tide databases with the acquired fragmentation pattern by the soft-
ware program Sequest (Thermo Finnigan).33 The modiﬁcations of
14.016, 28.0313, and 42.0470 mass units to lysine and arginine were
included in the database searches to determine mono-, di-, and tri-
methylation. All databases include a reversed version of all the se-
quences, and the data were ﬁltered to 1%–2% peptide false discovery
rate.34 The amino acid numbering of methylated residues is based on
the numbering of the reference cDNA (GenBank accession number
L12392) for both Q23- and Q78-huntingtin.
The score for each methylated lysine residue was calculated based on
the equation below:






where A is the number of MS-detected methylated peptides of
huntingtin, B is the number of MS-detected methylated peptides of
MS3 aptamer-bound huntingtin; and C is the number of MS-detected
methylated peptides of GCdx aptamer-bound huntingtin.
Immunoprecipitation
To investigate the effect of aptamer binding on the physical interac-
tions of huntingtin, pre-assembled human PRC2 complex and
puriﬁed Q78-huntingtin protein were subjected to co-immunopre-
cipitation (IP). 2 mg of PRC2 complex and 2 mg of Q78-huntingtin
protein pre-incubated with indicated DNA aptamers (MS1, MS2,MS3, or MS4) in 10-fold molar excess were incubated together for
1 hr at room temperature in IP buffer (50 mM Tris-HCl [pH 8.0],
150 mM NaCl, and 0.5 mM EDTA). 1 mg of anti-EZH2 antibody
(BD Biosciences) or anti-huntingtin antibody (HP-1) was added sub-
sequently and further incubated for 1 hr at room temperature. The
antigen-antibody complex was pulled down by the addition of
50 mL of protein-A agarose slurry (Roche Applied Science) and incu-
bated for 1 hr at room temperature. The immune complex was boiled
in LDS sample buffer (NuPAGE) for 10 min. The eluted samples were
separated by SDS-PAGE and subjected to immunoblotting with anti-
huntingtin or anti-EZH2 antibodies.
Cell-free Assay for PRC2 Methyltransferase Activity
Puriﬁcation of pre-assembled human PRC2 complex and preparation
of the G5E4 nucleosomal array were carried out as previously
described.9 The reconstituted in vitro PRC2 activity assay was also
performed similarly to the previous study9 except for the following
items: the reactions were done using 40 nM pre-assembled human
PRC2 complex and puriﬁed Q78-huntingtin protein pre-incubated
with indicated DNA aptamers after removing unbound aptamers
using a spin column.
Cell Culture and Aptamers Transfection
To investigate cellular H3K27me3 level in various HD cellular
models, we grew mouse embryonic stem cells (ESCs; HdhQ20/7
and HdhQ111/7), immortalized mouse striatal cells (STHdhQ7/7 and
STHdhQ111/111), and human NPCs (HD17m8 and HD60i4) as pre-
viously described.9,18,35 In brief, ESCs were maintained at 37C on
feeder layers of g-irradiated mouse embryonic ﬁbroblasts (Global
Stem Sciences) or on gelatin-coated plates (1% gelatin solution;
Millipore). Embryonic stem cell media contained Knock-Out
D-MEM (Invitrogen), 15% FBS (Hyclone), 50 IU/mL penicillin,
50 mg/mL streptomycin (Invitrogen), 0.2 mM GlutaMAX (Invitro-
gen), 0.1 mM non-essential amino acids (Invitrogen), 0.1 mM
2-mercaptoethanol (Sigma-Aldrich), and 1000 U/mL leukemia
inhibitory factor (LIF) (Millipore). The striatal cells were grown at
33C in DMEM supplemented with 10% fetal bovine serum, 1%
non-essential amino acids, 2 mM L-glutamine, and 400 mg/mL
G418 (Geneticin; Invitrogen). Human NPC line HD17m8 was a
generous gift of Dr. Steven J. Haggarty and was generated through
directed differentiation of human iPSC GM08330 as described pre-
viously.35 HD NPC line HD60i4 was generated from human iPSC
HD60i4 as described previously.18 HD60i-derived NPCs, expressing
mutant huntingtin with a 62-glutamine tract, as well as normal hun-
tingtin with a 20-glutamine segment, and HD17m8 NPCs from a
normal individual, expressing huntingtins with a 19-glutamine
segment have been described previously.18 Cells were maintained
on a poly-L-ornithine- and laminin-coated six-well plate (Falcon)
at 37C in neural expansion media (70% DMEM, 30% Hams F12,
1X B27 Supplement, 1% penicillin/ streptomycin, with 20 ng/ml
ﬁbroblast growth factor (FGF), 20 ng/ml epidermal growth factor
(EGF), and 5 mg/ml heparin freshly added just before use). In order
to stabilize single-stranded MS3 and GCdx DNA aptamers in cells,
they were synthesized to include the ﬁve bases at both 50 and 30 endsMolecular Therapy: Nucleic Acids Vol. 11 June 2018 425
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cent dye at the 50 end to be tracked in cells. Both NPC lines were
transfected with indicated DNA aptamers using Viromer Black re-
agent (Lipocalyx), and all immunoﬂuorescence experiments and
bead-based cellular PRC2 activity assays were performed after
24 hr of incubation. The 6-FAM signal intensities of both MS3
and GCdx aptamers in NPCs were observed similarly after 48 hr
of incubation (data not shown), indicating that they are stable in
cells at least up to 48 hr.
Immunofluorescence
Human NPCs were grown on poly-L-ornithine- and laminin-coated
coverslips for 24 hr, and after the experimental procedure, the cells
were ﬁxed with ice-cold methanol:acetone (1:1) for 5 min at
20C, washed thrice, and permeabilized in 0.1% Triton X-100 in
PBS for 5 min at room temperature. Cells were washed thrice with
PBS and blocked with 10% FBS in PBS for 2 hr at 4C. mAb2170 anti-
body (Millipore) was diluted as needed (1:250) in 10% FBS in PBS
and incubated overnight at 4C. Cells were washed again thrice
with PBS and incubated with Alexa 555-conjugated secondary anti-
body (Molecular Probes) for 1 hr at room temperature and mounted
in PermaFluor AqueousMountant (Lab Vision). Fluorescence images
were captured at 63 magniﬁcation equipped with an SP5 AOBS
scanning laser confocal microscope (Leica Microsystems).
Image Analysis
Identical image acquisition settings were used for like-stained sam-
ples. ImageJ/Fiji (coloc2 plugin and “analyze particle” module) were
used for co-localization analysis and for measuring FAM-MS3 and
FAM-GCdx puncta diameter. Nuclei were identiﬁed by DAPI stain-
ing (a threshold was applied and “analyze particles”was used to create
a nuclei mask). For co-localization analysis of FAM-MS3 and hun-
tingtin, the “subtract background” module was applied to each chan-
nel with a deﬁned rolling ball radius, which was 50 for the FAM-MS3
channel and 40 for the huntingtin (mAb2170) channel. Background-
subtracted channels, with the masks as guides, were then analyzed
with the coloc2 plugin. Pearson’s correlation coefﬁcients were calcu-
lated with size exclusion, and threshold was applied to determine the
relative degree of co-localization. For measuring the diameter of
FAM-MS3 puncta, cell bodies were identiﬁed on the DAPI channel
using a maximum ﬁlter with a radius of 140 to create a cell bodies
mask, from which the identiﬁed nuclei were then subtracted to create
a region of interest, “biomask.” The “subtract background” module
was applied to the FAM-MS3 and the FAM-GCdx channel with a
rolling ball radius of 12. Then the “analyze particle” module was per-
formed to measure the diameter of each FAM-MS3 and FAM-GCdx
puncta, and the number of puncta possessing a diameter size above
two pixels was then plotted.
Bead-Based Cellular PRC2 Activity Assay
The cellular assay for PRC2 was performed in accordance with the
manufacturer’s instruction (PerkinElmer). In brief, human NPCs
were seeded on a poly-L-ornithine- and laminin-coated 96-well plate
for 2 hr. Cells were transfected with indicated DNA aptamers using426 Molecular Therapy: Nucleic Acids Vol. 11 June 2018Viromer Black reagent (Lipocalyx) and incubated for 24 hr. After
removal of the original culture medium, cell-histone lysis and extrac-
tion buffers were sequentially added to the cells. For AlphaLISA
detection, histone extracts were transferred to wells of a 1/2
AreaPlate-96. The mixture of biotinylated anti-Histone H3 antibody
and anti-H3K27me3 Acceptor beads in cell-histone detection buffer
was added. Following a 60-min incubation at 23C, streptavidin-con-
jugated donor beads were then added, and a ﬁnal 30-min incubation
was performed prior to plate reading with Enspire Alpha Reader
(PerkinElmer). This optimized AlphaLISA H3K27me3 assay detected
increased H3K27me3 signal/cell in heterozygous HdhQ111/7 CAG
repeat knockin embryonic stem cells, expressing mutant huntingtin
with 111 glutamines and wild-type mouse 7-glutamine huntingtin,
compared with counterpart HdhQ20/7 Htt CAG knockin embryonic
stem cells, expressing 20-glutamine huntingtin along with wild-type
mouse huntingtin (Figure S6A), and yielded similar results for
111-glutamine huntingtin expressing STHdhQ111/Q111 striatal cells,
compared with their STHdhQ7/Q7 wild-type huntingtin-expressing
counterparts (Figure S6B), although with dramatically lower signal/
cell, as expected for the developmental stage-appropriate drop in
levels of the H3K27me3 mark.16
Cellular ATP Content Measurement
TheATP levels of humanNPCsweremeasured byCellTiter-GloLumi-
nescent Assay kit (Promega). In brief, following the aptamer transfec-
tion and incubation period, the cells were incubated with a volume of
CellTiter-Glo reagent equal to the volume of cell culture medium.
Following 30-min incubation at room temperature, the ATP level of
metabolically active cells was measured using a luminometer, and
the experiments were repeated four times. ATP standard curve was
generated by serial 10-fold dilutions of ATP disodium salt (Sigma-
Aldrich) in culture medium (0, 1, 10, or 100 pmol). The ATP content
per cell was determined with reference to ATP standards.
Cell Viability Assay under Various Stress Conditions
In order to compare the vulnerability between normal and HD
human NPCs against three different stresses, starvation, oxidative
stress and DNA damage, they were incubated with Hank’s balanced
salt solution (HBSS; Sigma-Aldrich),36 culture medium containing
hydrogen peroxide (H2O2; Sigma-Aldrich), or doxorubicin (Sigma-
Aldrich), respectively, after transfection of Mock, MS3, or GCdx
and subsequent 24-hr incubation. The cells were further incubated
in 10-fold diluted PrestoBlue reagent (Invitrogen) containing culture
medium for 1 hr at 37C, and the absorbance values were measured at
570 and 600 nm using a microplate reader. The 570 nm values were
normalized to the 600 nm values for the experimental wells and then
corrected with the control values generated from the wells containing
only culture media. The results were expressed as a percentage of un-
treated control cells (set at 100%).
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight ﬁgures and four tables and
can be found with this article online at https://doi.org/10.1016/j.
omtn.2018.03.008.
www.moleculartherapy.orgAUTHOR CONTRIBUTIONS
B.S., R.V., M.E.M., and I.S.S. developed the concept. B.S., R.J., H.O.,
G.E.O., H.L., S.L.C., J.-M.L., J.-J.S., R.V., S.K., R.L., and I.S.S. designed
the experiments and analyzed the data. B.S., R.J., and R.V. produced
and puriﬁed proteins. R.V. performed aptamer screening using LC
science platform and ELISA validation experiments, and R.V. and
J.-M.L. analyzed the data. G.E.O. performed thioﬂavin T ﬂuorescence
assay. R.V. performed the aptamer binding experiment with caspase-
6 cleavage. H.L. and J.-J.S. performed the aptamer binding experiment
using SLM reaction, and B.S. analyzed the data. R.J. and B.S. validated
MS aptamer binding sites with KDmutants. R.V. performed hunting-
tin interaction and cell-free activity experiments with PRC2. B.S.
performed the binding experiment of MS3 with NPC lysates and
bead-based PRC2 assay. B.S., H.O., and S.L.C. performed immunoﬂu-
orescence experiments and analyzed the confocal image data. B.S.,
R.J., H.L., J.-J.S., R.V., and I.S.S. wrote the paper, which was signiﬁ-
cantly revised by S.K., R.L., and M.E.M.
CONFLICTS OF INTEREST
The authors declare no competing ﬁnancial interests.
ACKNOWLEDGMENTS
We thank the members of the Cotman, Song, and Seong laboratories
for suggestions and discussions. We are grateful to Dr. Ross Tomaino
(the Taplin Mass spectrometry facility) for excellent technical sup-
port. This work was supported by the CHDI Foundation Inc.
(J.-M.L., M.E.M., and I.S.S.), the NIH/National Institute of Neurolog-
ical Disorders and Stroke (grant R01 NS079651 to I.S.S.), and a Global
Research Laboratory grant from the National Foundation of Korea
(grant NRF-2016K1A1A2912057 to I.S.S. and J.S.).
REFERENCES
1. The Huntington’s Disease Collaborative Research Group (1993). A novel gene con-
taining a trinucleotide repeat that is expanded and unstable on Huntington’s disease
chromosomes. Cell 72, 971–983.
2. Snell, R.G., MacMillan, J.C., Cheadle, J.P., Fenton, I., Lazarou, L.P., Davies, P.,
MacDonald, M.E., Gusella, J.F., Harper, P.S., and Shaw, D.J. (1993). Relationship be-
tween trinucleotide repeat expansion and phenotypic variation in Huntington’s dis-
ease. Nat. Genet. 4, 393–397.
3. Lee, J.M., Ramos, E.M., Lee, J.H., Gillis, T., Mysore, J.S., Hayden, M.R., Warby, S.C.,
Morrison, P., Nance, M., Ross, C.A., et al.; PREDICT-HD study of the Huntington
Study Group (HSG); REGISTRY study of the European Huntington’s Disease
Network; HD-MAPS Study Group; COHORT study of the HSG (2012). CAG repeat
expansion in Huntington disease determines age at onset in a fully dominant fashion.
Neurology 78, 690–695.
4. Gusella, J.F., and MacDonald, M.E. (2000). Molecular genetics: unmasking polyglut-
amine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1, 109–115.
5. Di Prospero, N.A., and Fischbeck, K.H. (2005). Therapeutics development for triplet
repeat expansion diseases. Nat. Rev. Genet. 6, 756–765.
6. Takano, H., and Gusella, J.F. (2002). The predominantly HEAT-like motif structure
of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/
Rel/dorsal family transcription factor. BMC Neurosci. 3, 15.
7. Andrade, M.A., and Bork, P. (1995). HEAT repeats in the Huntington’s disease pro-
tein. Nat. Genet. 11, 115–116.
8. Vijayvargia, R., Epand, R., Leitner, A., Jung, T.Y., Shin, B., Jung, R., Lloret, A., Singh
Atwal, R., Lee, H., Lee, J.M., et al. (2016). Huntingtin’s spherical solenoid structureenables polyglutamine tract-dependent modulation of its structure and function.
eLife 5, e11184.
9. Seong, I.S., Woda, J.M., Song, J.J., Lloret, A., Abeyrathne, P.D., Woo, C.J., Gregory, G.,
Lee, J.M., Wheeler, V.C., Walz, T., et al. (2010). Huntingtin facilitates polycomb
repressive complex 2. Hum. Mol. Genet. 19, 573–583.
10. Kaur, G., and Roy, I. (2008). Therapeutic applications of aptamers. Expert Opin.
Investig. Drugs 17, 43–60.
11. Keefe, A.D., Pai, S., and Ellington, A. (2010). Aptamers as therapeutics. Nat. Rev.
Drug Discov. 9, 537–550.
12. Gabelica, V., Maeda, R., Fujimoto, T., Yaku, H., Murashima, T., Sugimoto, N., and
Miyoshi, D. (2013). Multiple and cooperative binding of ﬂuorescence light-up probe
thioﬂavin T with human telomere DNA G-quadruplex. Biochemistry 52, 5620–5628.
13. Renaud de la Faverie, A., Guédin, A., Bedrat, A., Yatsunyk, L.A., and Mergny, J.L.
(2014). Thioﬂavin T as a ﬂuorescence light-up probe for G4 formation. Nucleic
Acids Res. 42, e65.
14. Wellington, C.L., Singaraja, R., Ellerby, L., Savill, J., Roy, S., Leavitt, B., Cattaneo, E.,
Hackam, A., Sharp, A., Thornberry, N., et al. (2000). Inhibiting caspase cleavage of
huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal
cells. J. Biol. Chem. 275, 19831–19838.
15. Sledz, P., Zheng, H., Murzyn, K., Chruszcz, M., Zimmerman, M.D., Chordia, M.D.,
Joachimiak, A., and Minor, W. (2010). New surface contacts formed upon reductive
lysine methylation: improving the probability of protein crystallization. Protein Sci.
19, 1395–1404.
16. Biagioli, M., Ferrari, F., Mendenhall, E.M., Zhang, Y., Erdin, S., Vijayvargia, R.,
Vallabh, S.M., Solomos, N., Manavalan, P., Ragavendran, A., et al. (2015). Htt
CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in
chromatin regulation. Hum. Mol. Genet. 24, 2442–2457.
17. von Schimmelmann, M., Feinberg, P.A., Sullivan, J.M., Ku, S.M., Badimon, A., Duff,
M.K., Wang, Z., Lachmann, A., Dewell, S., Ma’ayan, A., et al. (2016). Polycomb
repressive complex 2 (PRC2) silences genes responsible for neurodegeneration.
Nat. Neurosci. 19, 1321–1330.
18. HDiPSC Consortium (2012). Induced pluripotent stem cells from patients with
Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell
Stem Cell 11, 264–278.
19. Seong, I.S., Ivanova, E., Lee, J.M., Choo, Y.S., Fossale, E., Anderson, M., Gusella, J.F.,
Laramie, J.M., Myers, R.H., Lesort, M., andMacDonald, M.E. (2005). HDCAG repeat
implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Hum. Mol. Genet. 14, 2871–2880.
20. Jacobsen, J.C., Gregory, G.C., Woda, J.M., Thompson, M.N., Coser, K.R., Murthy, V.,
Kohane, I.S., Gusella, J.F., Seong, I.S., MacDonald, M.E., et al. (2011). HDCAG-corre-
lated gene expression changes support a simple dominant gain of function. Hum.
Mol. Genet. 20, 2846–2860.
21. Nath, S., Munsie, L.N., and Truant, R. (2015). A huntingtin-mediated fast stress
response halting endosomal trafﬁcking is defective in Huntington’s disease. Hum.
Mol. Genet. 24, 450–462.
22. Swan, C.L., and Sistonen, L. (2015). Cellular stress response cross talk maintains pro-
tein and energy homeostasis. EMBO J. 34, 267–269.
23. Ayala-Peña, S. (2013). Role of oxidative DNA damage in mitochondrial dysfunction
and Huntington’s disease pathogenesis. Free Radic. Biol. Med. 62, 102–110.
24. Maiuri, T., Mocle, A.J., Hung, C.L., Xia, J., van Roon-Mom, W.M., and Truant, R.
(2017). Huntingtin is a scaffolding protein in the ATM oxidative DNA damage
response complex. Hum. Mol. Genet. 26, 395–406.
25. Skogen, M., Roth, J., Yerkes, S., Parekh-Olmedo, H., and Kmiec, E. (2006). Short
G-rich oligonucleotides as a potential therapeutic for Huntington’s Disease. BMC
Neurosci. 7, 65.
26. Yerkes, S., Vesenka, J., and Kmiec, E.B. (2010). A stable G-quartet binds to a huntingtin
protein fragment containing expandedpolyglutamine tracks. J.Neurosci. Res.88, 335–345.
27. Chaudhary, R.K., Patel, K.A., Patel, M.K., Joshi, R.H., and Roy, I. (2015). Inhibition of
aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast
model of Huntington’s disease. Mol. Ther. 23, 1912–1926.
28. Brázda, V., Hároníková, L., Liao, J.C., and Fojta, M. (2014). DNA and RNA quadru-
plex-binding proteins. Int. J. Mol. Sci. 15, 17493–17517.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 427
Molecular Therapy: Nucleic Acids29. Rhodes, D., and Lipps, H.J. (2015). G-quadruplexes and their regulatory roles in
biology. Nucleic Acids Res. 43, 8627–8637.
30. Gatto, B., Palumbo, M., and Sissi, C. (2009). Nucleic acid aptamers based on the
G-quadruplex structure: therapeutic and diagnostic potential. Curr. Med. Chem.
16, 1248–1265.
31. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996). Mass spectrometric
sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850–858.
32. Peng, J., and Gygi, S.P. (2001). Proteomics: the move to mixtures. J. Mass Spectrom.
36, 1083–1091.
33. Eng, J.K., McCormack, A.L., and Yates, J.R. (1994). An approach to correlate tandem
mass spectral data of peptides with amino acid sequences in a protein database. J. Am.
Soc. Mass Spectrom. 5, 976–989.428 Molecular Therapy: Nucleic Acids Vol. 11 June 201834. Beausoleil, S.A., Villén, J., Gerber, S.A., Rush, J., and Gygi, S.P. (2006). A probability-
based approach for high-throughput protein phosphorylation analysis and site local-
ization. Nat. Biotechnol. 24, 1285–1292.
35. Sheridan, S.D., Theriault, K.M., Reis, S.A., Zhou, F., Madison, J.M., Daheron, L.,
Loring, J.F., and Haggarty, S.J. (2011). Epigenetic characterization of the FMR1
gene and aberrant neurodevelopment in human induced pluripotent stem cell models
of fragile X syndrome. PLoS ONE 6, e26203.
36. Shang, L., Chen, S., Du, F., Li, S., Zhao, L., and Wang, X. (2011). Nutrient starva-
tion elicits an acute autophagic response mediated by Ulk1 dephosphorylation
and its subsequent dissociation from AMPK. Proc. Natl. Acad. Sci. USA 108,
4788–4793.
